Challenges in developing a validated biomarker for angiogenesis inhibitors: The motesanib experience

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Bass, Michael B ^a   Yao, Bin ^a   Hei, Yong Jiang ^a   Ye, Yining ^a   Davis, Gerard J ^b   Davis, Michael T ^a   Kaesdorf, Barbara A ^b   Chan, Sabrina S ^b   Patterson, Scott D ^a  

^a AMGEN INC   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; MOTESANIB; PACLITAXEL; PLACEBO; PLACENTAL GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMETELSTAT; INDOLE DERIVATIVE; NICOTINAMIDE; PLACENTA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; SURVIVAL TIME; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PACLITAXEL; PLACEBO EFFECT; PREGNANCY PROTEINS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908110273     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108048     Document Type: Article

References (41)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
2. Korpanty G, Smyth E (2012) Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. Curr Pharm Des 18: 2680-2701.
3. Sharma PS, Sharma R, Tyagi T (2011) VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 11: 624-653.
4. Blumenschein GR Jr (2012) Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs 30: 1802-1811.
5. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol: doi: 10.1200/ JCO.2012.1246.2762.
6. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, et al. (2014) A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015). J Thorac Oncol 9: 848-855.
7. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, et al. (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66: 8715-8721.
8. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, et al. (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376.
9. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, et al. (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27: 3794-3801.
10. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, et al. (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359: 31-42.
11. Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, et al. (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22: 2057-2067.
12. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, et al. (2001) Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 61: 2696-2703.
13. Cao Y, Linden P, Shima D, Browne F, Folkman J (1996) In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/ vascular endothelial growth factor. J Clin Invest 98: 2507-2511.
14. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
15. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840.
16. Autiero M, Luttun A, Tjwa M, Carmeliet P (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1: 1356-1370.
17. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG (2005) Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3: 68.
18. Bass MB, Davis MT, Kivman L, Khoo HM, Notari K, et al. (2010) Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small-cell lung cancer, and locally recurrent or advanced metastatic breast cancer [abstract]. J Clin Oncol 28: 3037.
19. Patterson SD, Davis MT, Mackey J, Martin M, Hei YJ, et al. (2010) Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (Pts) with locally recurrent or advanced metastatic breast cancer [abstract/poster]. J Clin Oncol 28: 1048.
20. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, et al. (2010) Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95: 5018-5027.
21. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, et al. (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748.
22. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, et al. (2010) Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70: 2171-2179.
23. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27: 3020-3026.
24. Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, et al. (2011) Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib. Clin Cancer Res 17: 1190-1199.
25. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, et al. (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGFrelated proteins. J Transl Med 5: 32.
26. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, et al. (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823.
27. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, et al. (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30: 2829-2836.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
29. Russell CB, Suggs S, Robson KM, Kerkof K, Kivman LD, et al. (2008) Biomarker sample collection and handling in the clinical setting to support early phase drug development. In: Wang F, editor. Biomarker Methods in Drug Discovery and Development. Totowa, NJ: Humana Press. 1-26
30. Cox DR, Oakes D (1984) Analysis of Survival Data. Boca Raton, FL: Chapman & Hall/CRC.
31. Miller R, Siegmund D (1982) Maximally selected chi square statistics. Biometrics 38: 1011-1016.
32. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344.
33. Kutner M, Nachtsheim C, Neter J, Li W (2005) Applied Linear Statistical Models. New York, NY: McGraw Hill/Irwin. 1-26 p.
34. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc B 57: 289-300.
35. Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 255-268.
36. Freidlin B, McShane LM, Polley MY, Korn EL (2012) Randomized phase II trial designs with biomarkers. J Clin Oncol 30: 3304-3309.
37. Hung HM, Wang SJ, O'Neill RT (2006) Methodological issues with adaptation of clinical trial design. Pharm Stat 5: 99-107.
38. Metcalfe TA (2010) Development of novel IVD assays: a manufacturer's perspective. Scand J Clin Lab Invest Suppl 242: 23-26.
39. Korn EL, McShane LM, Freidlin B (2013) Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med 5: 178sr173.
40. Kern SE (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 72: 6097-6101.
41. US Food and Drug Administration (2010) Guidance for industry: qualification process for drug development tools (draft guidance). Rockville, MD.